BR0116420A - proteìnas moduladoras de receptores de glutamato e moléculas de ácidos nucléicos e aplicações das mesmas - Google Patents
proteìnas moduladoras de receptores de glutamato e moléculas de ácidos nucléicos e aplicações das mesmasInfo
- Publication number
- BR0116420A BR0116420A BRPI0116420-1A BR0116420A BR0116420A BR 0116420 A BR0116420 A BR 0116420A BR 0116420 A BR0116420 A BR 0116420A BR 0116420 A BR0116420 A BR 0116420A
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- mglur5m
- proteins
- acid molecules
- applications
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Psychology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
Abstract
"PROTEìNAS MODULADORAS DE RECEPTORES DE GLUTAMATO E MOLéCULAS DE áCIDOS NUCLéICOS E APLICAçõES DAS MESMAS". São revelados novos peptídeos mGluR5M, proteínas, e moléculas de ácidos nucléicos. Além de proteínas mGluR5M de extensão completa isoladas, a invenção fornece ainda proteínas de fusão mGluR5M isoladas, peptídeos antigênicos e anticorpos anti- mGluR5M. A invenção também fornece moléculas de ácidos nucléicos mGluR5M, vetores de expressão recombinante contendo uma molécula de ácido nucléico da invenção, células hospedeiras nas quais os vetores de expressão foram introduzidos e animais transgênicos não humanos nos quais um gene mGluR5M foi introduzido ou rompido. Também são fornecidos métodos diagnósticos, de varredura e terapêuticos utilizando composições da invenção.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25758900P | 2000-12-22 | 2000-12-22 | |
| PCT/US2001/049817 WO2002070708A2 (en) | 2000-12-22 | 2001-12-21 | Glutamate receptor modulatory proteins and nucleic acids encoding them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0116420A true BR0116420A (pt) | 2006-02-21 |
Family
ID=22976904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0116420-1A BR0116420A (pt) | 2000-12-22 | 2001-12-21 | proteìnas moduladoras de receptores de glutamato e moléculas de ácidos nucléicos e aplicações das mesmas |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20020142330A1 (pt) |
| EP (1) | EP1390496A2 (pt) |
| JP (1) | JP2004537277A (pt) |
| KR (1) | KR20030074675A (pt) |
| CN (1) | CN1714151A (pt) |
| BR (1) | BR0116420A (pt) |
| CA (1) | CA2432280A1 (pt) |
| IL (1) | IL156519A0 (pt) |
| MX (1) | MXPA03005428A (pt) |
| WO (1) | WO2002070708A2 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69637587D1 (de) * | 1995-07-26 | 2008-08-21 | Astrazeneca Ab | Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen |
| US20050186658A1 (en) * | 2003-10-17 | 2005-08-25 | Nps Pharmaceuticals, Inc. | Chimeric metabotropic glutamate receptors and uses thereof |
| WO2005075989A1 (en) * | 2004-01-28 | 2005-08-18 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human metabotropic glutamate receptor 5 (mglur5) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869609A (en) * | 1990-12-12 | 1999-02-09 | Zymogenetics, Inc. | G protein coupled glutamate receptors |
| US5521297A (en) * | 1993-06-04 | 1996-05-28 | Salk Institute Biotechnology/Industrial Associates | Nucleic acids encoding human metabotropic glutamate receptors |
| US6001581A (en) * | 1993-06-04 | 1999-12-14 | Sibia Neurosciences, Inc. | Cation-based bioassay using human metabotropic glutamate receptors |
| US6211353B1 (en) * | 1994-07-29 | 2001-04-03 | Eli Lilly And Company | Isolated nucleic acid encoding a human mGluR5 |
| DE69637587D1 (de) * | 1995-07-26 | 2008-08-21 | Astrazeneca Ab | Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen |
| AU2486999A (en) * | 1998-01-30 | 1999-08-16 | University Technology Corporation | Polynucleotide and polypeptide sequences associated with cns depressant sensitivity and methods of use thereof |
| WO2001002566A1 (en) * | 1999-07-02 | 2001-01-11 | Neurocrine Biosciences, Inc. | Metabotropic glutamate receptors and methods of use therefor |
| US6534287B1 (en) * | 1999-10-25 | 2003-03-18 | Nps Pharmaceuticals, Inc. | Human metabotropic glutamate receptor |
| AU2001251199A1 (en) * | 2000-04-06 | 2001-10-23 | Genetics Institute, Llc. | Polynucleotides encoding novel secreted proteins |
-
2001
- 2001-12-21 CN CNA018228062A patent/CN1714151A/zh active Pending
- 2001-12-21 IL IL15651901A patent/IL156519A0/xx unknown
- 2001-12-21 WO PCT/US2001/049817 patent/WO2002070708A2/en not_active Ceased
- 2001-12-21 EP EP01272486A patent/EP1390496A2/en not_active Withdrawn
- 2001-12-21 KR KR10-2003-7008495A patent/KR20030074675A/ko not_active Withdrawn
- 2001-12-21 CA CA002432280A patent/CA2432280A1/en not_active Abandoned
- 2001-12-21 MX MXPA03005428A patent/MXPA03005428A/es unknown
- 2001-12-21 BR BRPI0116420-1A patent/BR0116420A/pt not_active IP Right Cessation
- 2001-12-21 US US10/027,923 patent/US20020142330A1/en not_active Abandoned
- 2001-12-21 JP JP2002570733A patent/JP2004537277A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1390496A2 (en) | 2004-02-25 |
| KR20030074675A (ko) | 2003-09-19 |
| JP2004537277A (ja) | 2004-12-16 |
| WO2002070708A3 (en) | 2003-12-04 |
| CA2432280A1 (en) | 2002-09-12 |
| MXPA03005428A (es) | 2003-09-10 |
| IL156519A0 (en) | 2004-01-04 |
| US20020142330A1 (en) | 2002-10-03 |
| WO2002070708A2 (en) | 2002-09-12 |
| CN1714151A (zh) | 2005-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0013542A (pt) | Moléculas b7-4 e usos para as mesmas | |
| DE60035517D1 (de) | Gl50 moleküle, sowie verwendungen derselben | |
| ATE353965T1 (de) | An g-protein gekoppelte rezeptoren und deren verwendungen | |
| ATE419358T1 (de) | Gebrauchsverfaheren eines neuen lysyloxidase- verwandten proteins | |
| BR0109524A (pt) | Molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um polipeptìdeo, polipeptìdeo isolado, anticorpo, método para detectar a presença de um polipeptìdeo em uma amostra, kit, e, métodos para detectar a presença de uma molécula de ácido nucleico em uma amostra, para identificar um composto e para modular a atividade de um polipeptìdeo | |
| ATE449173T1 (de) | 32144, eine humane fettsäureamid-hydrolase und deren verwendungen | |
| BR0116420A (pt) | proteìnas moduladoras de receptores de glutamato e moléculas de ácidos nucléicos e aplicações das mesmas | |
| EP1412374A4 (en) | NEW PGC-1 ISOFORMS AND THEIR USES | |
| DE60142356D1 (de) | 18480 humane proteinkinasemoleküle und ihre verwendungen | |
| BR0114383A (pt) | Interatuadores de canais de potássio e aplicações dos mesmos | |
| DE60138952D1 (de) | 16836, ein mitglied der humanen phospholipase c familie und seine verwendungen | |
| DE60137222D1 (de) | Humanes trp-ähnliches kalziumkanalprotein-2 tlcc-2 | |
| BR0210937A (pt) | Receptor acoplado à proteìna g, gave 3 | |
| WO2002010391A3 (en) | 18610, a human transient receptor and uses thereof | |
| DE60124910D1 (de) | Menschliche twik-8 moleküle und ihre verwendung | |
| BR0213029A (pt) | Receptor acoplado por proteìna g, gave10 | |
| DK1328621T3 (da) | 13245, en ny human proteinkinase af den myotoniske dystrofitype og anvendelser deraf | |
| DE60136832D1 (de) | Atcr-1, eine humane acyltransferase und verwendungen davon | |
| DE60139153D1 (de) | 14189, eine humane kinase und deren verwendungen | |
| DE60234047D1 (de) | 15603, ein mitglied der humanen ionenkanal-familie | |
| WO2001068806A3 (en) | 26934, a novel cytidine deaminase-like molecule and uses thereof | |
| ATE476194T1 (de) | Ein mitglied der menschlichen proteinkinasefamilie, und verwendungen dafür | |
| BR0211338A (pt) | Receptor acoplado à proteìna g, gave8 | |
| ATE331033T1 (de) | Proteinkinase-molekül 14911 und dessen anwendungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 7A. ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009. |